The Latest Breaking News from Organon

The race for the White House is heating up and these five stocks are set to benefit if Kamala Harris claims victory.

Gen Z is having a hard time getting entry-level jobs, plus companies are hiring fewer interns.

Australians’ access to a range of contraceptive options depends on where they live and how wealthy they are. A recent parliamentary inquiry recommends ways to end this “postcode lottery” for people who want to use long-acting reversible contraception.

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

Unintended pregnancy remains a significant global health issue. A recent UNFPA report suggesting nearly half of all pregnancies, totaling 121 million each year worldwide, are unintended and more than 160 million women have limited access to contraceptives.

Upgrades

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Upgrades